http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109705221-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577 |
| filingDate | 2018-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109705221-B |
| titleOfInvention | C peptide immunogen, monoclonal antibody pair thereof and application of antibody pair in C peptide magnetic particle chemiluminescence immunoassay reagent |
| abstract | The invention provides a C peptide immunogen, which comprises a first complete antigen and a second complete antigen, wherein the first complete antigen is obtained by coupling a C peptide N-terminal amino acid sequence with a carrier protein, and the second complete antigen is obtained by coupling a C peptide C-terminal amino acid sequence with the carrier protein; the N-terminal amino acid sequence of the C peptide of the first complete antigen is a sequence from 1 to 12 bits in the full-length sequence of the C peptide, and the C-terminal amino acid sequence of the C peptide of the second complete antigen is a sequence from 18 to 31 bits in the full-length sequence of the C peptide. The antigen can be obtained by the existing synthetic method and is an available complete antigen, the preparation method is simple, and the obtained complete antigen has a stable structure; the monoclonal antibody pair obtained by animal immunization can be respectively and specifically combined with the N end and the C end of the C peptide, and the combination sites are far away, so that the situation that pairing cannot be carried out due to steric hindrance is avoided, and the requirements of developing C peptide magnetic particle chemiluminescence immunodiagnosis reagents and other immunological diagnosis reagents on the antibodies can be met. |
| priorityDate | 2018-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 121.